Theravance Biopharma TBPH Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's total liabilities & equity?
- Theravance Biopharma (TBPH) reported total liabilities & equity of $472.31M in Q1 2026.
- How has Theravance Biopharma's total liabilities & equity changed year-over-year?
- Theravance Biopharma's total liabilities & equity increased by 37.5% year-over-year, from $343.58M to $472.31M.
- What is the long-term trend for Theravance Biopharma's total liabilities & equity?
- Over 5 years (2020 to 2025), Theravance Biopharma's total liabilities & equity has grown at a 0.7% compound annual growth rate (CAGR), from $469.06M to $485.57M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.